Shares of Coherus Biosciences Inc (NASDAQ:CHRS) have received an average rating of “Buy” from the eleven research firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $32.00.
CHRS has been the topic of a number of analyst reports. BidaskClub raised Coherus Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Citigroup reaffirmed a “buy” rating and issued a $23.00 price target on shares of Coherus Biosciences in a research report on Tuesday, November 7th. Zacks Investment Research raised Coherus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Wednesday, January 3rd. Finally, ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd.
Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc raised its position in shares of Coherus Biosciences by 12.6% during the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,046 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Coherus Biosciences during the 4th quarter worth about $101,000. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Coherus Biosciences by 497.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 10,491 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Coherus Biosciences during the 2nd quarter worth about $185,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Coherus Biosciences during the 4th quarter worth about $116,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.
About Coherus Biosciences
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.